RxDoctor Payments Data

Brian Kim, MD

Family Medicine · San Diego, CANPI 1114022522

Payments from drug & device makers

$2,160in general payments, 2019–2025

Across 91 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$334
  • GSK$136
  • Caris MPI, Inc.$128
  • Madrigal Pharmaceuticals$118
  • Lilly USA, LLC$73
  • plus $370 from 13 others

What the payments were for

  • Food & beverage$2,13799%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,160 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$153,424
Medicare patients
392
Services billed
1,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala142$653,754
TivicayDolutegravir Sodium36$105,285
DescovyEmtricitabine/Tenofov Alafenam22$62,873
TrulicityDulaglutide52$61,814
DovatoDolutegravir Sodium/Lamivudine13$39,470
OzempicSemaglutide32$33,908
EliquisApixaban23$32,092
PrezcobixDarunavir/Cobicistat11$26,790
PifeltroDoravirine12$20,789
Lamivudine-ZidovudineLamivudine/Zidovudine17$10,463
JanuviaSitagliptin Phosphate11$8,956
XareltoRivaroxaban12$7,803
Celecoxib48$3,813
Nevirapine24$3,196
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$2,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,001$716,627164 claims
Viiv Healthcare CompanyTivicay, Dovato$334$144,75549 claims
Lilly USA, LLCTrulicity$73$61,81452 claims
Johnson & JohnsonPrezcobix, Xarelto$24$34,59323 claims
Novo NordiskOzempic$40$33,90832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →